Showing 2451-2460 of 10226 results for "".
EXELO2 by Quantel Derma
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/exelo2-by-quantel-derma/19448/EXELO2 by Quantel Derma is a versatile laser system for fractional treatments and full ablation for the treatment of wrinkles and scars. Shape and size of the treatment area can be set directly at the scanner hand-piece. EXCELO2 offers Random Scanning for better aesthetic results and Full Ablation MDermatology and CTCL: Recommendations
https://practicaldermatology.com/series/dermwire-tv/dermatology-and-ctcl-recommendations/26798/Larisa J. Geskin, MD, Professor of Dermatology at Columbia University Medical Center, discusses "Time to Act: A Global Patient-Focused Consensus for Improving Care in Cutaneous T-Cell Lymphoma (CTCL)," a global consensus statement from Kyowa Kirin that recommends, among other things, that dermatologAntimicrobial Resistance and Psoriasis Remission
https://practicaldermatology.com/series/the-practical-dermatology-podcast/antimicrobial-resistance-and-psoriasis-remission/39042/Jason E. Hawkes, MD, MS, FAAD, discusses a recent consensus paper defining on-treatment remission for plaque psoriasis, and Theodore Rosen, MD, FAAD, joins associate medical editor Elizabeth (Lisa) Swanson, MD, FAAD, to discuss the threat posed by antimicrobial resistance and play “Two Truths and aPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 4
https://reachmd.com/programs/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-4/32760/Host Neal Bhatia, MD, FAAD, and guests Laura K. Ferris, MD, PhD, FAAD, and Jason E. Hawkes, MD, MS, FAAD, discuss updated guidelines for generalized pustular psoriasis treatment and evaluation in light of the current understanding of the IL-36 pathway, as well as the mechanism of action of spesolimaAnti-OX40 Ligand Antibody Trials
https://practicaldermatology.com/series/updates-atopic-dermatitis/anti-ox40-ligand-antibody-trials/29531/Lead study author Stephan Weidinger, MD, PhD, Director of the Department of Dermatology and Allergy at the University Hospital Schleswig-Holstein, discusses the phase 2b STREAM-AD trial, evaluating amlitelimab in adult patients with moderate-to-severe atopic dermatitis.The Activation of Itch
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37141/Practical Dermatology Editorial Board member Todd Schlesinger, MD, a board-certified dermatologist and Mohs surgeon with Epiphany Dermatology in Charleston, South Carolina, discusses the mechanism of itch.PDRN and Regenerative Medicine Update
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/pdrn-regenerative-medicine-update/39739/Suneel Chilukuri, MD, covers the latest in polydeoxyribonucleotide (PDRN) therapies and regenerative medicine applications in dermatology. This video was recorded at the Science of Skin Summit in Austin, TX.HS Tips and Lizards
https://practicaldermatology.com/series/the-practical-dermatology-podcast/hs-tips-and-lizards/35858/The latest news and updates, plus a psoriasis update from Jashin J. Wu, MD, FAAD, at Music City SCALE, and Jennifer L. Hsiao, MD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss treating hidradenitis suppurativa and play a game of "Two Truths and a Lie."When and How to Use Ancillary Testing
https://reachmd.com/programs/practical-dermatology-updates-in-skin-cancer/when-and-how-to-use-ancillary-testing/35598/Hadas Skupsky, MD, a board-certified dermatologist and dermatopathologist, discusses when a dermatopathologist decides to use ancillary testing for melanoma, how that impacts final diagnosis, and how it can guide treatment decisions.I Came In Like a Wrecking Ball
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/i-came-in-like-a-wrecking-ball/33162/I have to start by warning you, dear reader, that I am writing my first editorial for Practical Dermatology immediately after typing up four appeal letters to insurance companies.